Core Viewpoint - The company is actively pursuing international expansion and product innovation while addressing currency fluctuations and market competition challenges. Group 1: Stock Performance and Market Activity - As of February 10, 2026, the company's stock closed at 190.36 yuan, with a slight increase of 0.63% and a trading volume of 51,700 shares, resulting in a transaction value of 983 million yuan [1] - On February 10, 2026, there was a net inflow of 45.8035 million yuan from main funds, indicating significant buying interest [10] Group 2: International Listing and Regulatory Approvals - The company submitted an application for H-share listing on the Hong Kong Stock Exchange on November 10, 2025, which is pending approval from various regulatory bodies [2] Group 3: Currency Impact on Financial Performance - Approximately 50% of the company's sales revenue comes from overseas, primarily settled in USD and EUR, making it susceptible to fluctuations in the RMB exchange rate, which can affect revenue and profit margins [3] - The company is implementing strategies such as foreign exchange hedging and fixed-rate agreements to mitigate the impact of currency fluctuations on its business operations [3] Group 4: Product and Market Positioning - The company has established a strong global network in R&D, manufacturing, marketing, and service, with its six major product lines ranking among the top three in global markets [4] - As of June 30, 2025, the company's products were sold in over 190 countries, with overseas revenue accounting for approximately 45% of total revenue in 2024 [4] - In the European and American markets, the company achieved over 5.5 billion yuan in revenue in 2024, representing 15% of total revenue, highlighting its brand strength and sales growth [4] Group 5: AI and Innovation Strategy - The company emphasizes its commitment to medical AI, with applications in critical care and various clinical scenarios, although it faces challenges in market perception and growth potential [5] - There is a call for the company to enhance its corporate culture and innovation focus to bridge the gap with international competitors and improve product pricing power [6] Group 6: Shareholder Engagement and Future Plans - As of September 30, 2025, the total number of shareholders was 108,835 [7] - The company plans to release its annual report for 2025 on March 31, 2026, which will provide insights into its financial performance [8]

Core Insights - Company has established a comprehensive global network covering R&D, manufacturing, marketing, and services, laying a solid foundation for ongoing internationalization [2][4] - The six major product lines, including monitors, anesthesia systems, ventilators, defibrillators, blood cell analyzers, and ultrasound imaging devices, rank among the top three in global markets [2][4] - Company's products have been adopted by 87 out of the top 100 hospitals globally as per Newsweek, demonstrating strong market presence [2][4] Financial Performance - By June 30, 2025, products will be sold in over 190 countries and regions, with overseas revenue expected to account for approximately 45% of total revenue in 2024 [2][4] - Revenue from the European and American markets is projected to exceed RMB 5.5 billion in 2024, representing 15% of total revenue for that year [5] Market Position and Strategy - Company has successfully penetrated numerous top-tier medical institutions known for strict procurement standards, reflecting its international leadership in technological innovation, product reliability, and clinical application value [5] - In the U.S., the company has covered about 80% of IDN medical systems and over 2,100 IDN hospitals, with nearly 35% of these hospitals using two or more product combinations [5] - The company has also entered the top 30 hospitals in the U.S. and over 660 European teaching hospitals, positioning itself as a key player in the global healthcare market [5] Growth Opportunities - The accelerating trends in medical digitization, chronic disease management, home care, and aging population are driving demand for smart monitoring, precise diagnostics, and minimally invasive treatments in the European and American markets [5] - These trends provide significant growth opportunities for the company to enhance penetration in high-end medical systems and optimize its product structure [5]

Core Viewpoint - The company, Edan Instruments, forecasts a net profit attributable to shareholders of 284 million to 332 million yuan for 2025, representing a year-on-year growth of 75% to 105% [1] Group 1: Financial Performance - The company expects steady growth in overall revenue for 2025, particularly in international markets, which are projected to maintain double-digit growth [1] - Non-recurring gains and losses are anticipated to impact net profit by approximately 14 million yuan, mainly from government subsidies, which is a decrease of around 4 million yuan compared to the previous year [1] Group 2: Business Strategy - The company continues to focus on its development strategy of "innovation, platform-based, and internationalization," enhancing its global business layout and service capabilities in overseas markets [1] - Edan Instruments is accelerating new product development and optimizing its marketing system while advancing its overseas manufacturing strategy [2] - The company has been collaborating with the Gates Foundation, with progress on handheld ultrasound devices reaching clinical validation and confirmation stages [2] Group 3: Operational Developments - A new facility in the U.S. covering 1,940 square meters has been added to enhance the company's business layout in North America and improve supply chain resilience [2] - The new facility has received comprehensive certifications, including MDSAP certification and the California FDB medical device production license [2] - The company plans to flexibly arrange domestic and overseas production capacity based on order demand after the new U.S. facility is operational, which is expected to enhance profitability in the long term [3]

Group 1 - Mindray Medical has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International and JPMorgan serving as joint sponsors [1] - Mindray's six major product lines, including monitors, anesthesia systems, ventilators, defibrillators, blood cell analyzers, and ultrasound imaging equipment, rank among the top three in the global market [1] - The listing aims to build an international capital platform, with funds raised to enhance R&D and overseas expansion, potentially accelerating penetration into emerging markets and breakthroughs in high-end markets [1] Group 2 - Insilico Medicine has announced a strategic drug development collaboration with Eli Lilly, leveraging Insilico's AI drug discovery platform and Eli Lilly's expertise in drug development and disease research [2] - This collaboration signifies an upgrade in the partnership, building on a previous software licensing agreement established in 2023 [2] Group 3 - YuanDa Pharmaceutical has received a drug registration certificate from the National Medical Products Administration for its innovative drug, Laitling, which treats allergic rhinitis in adults and children [3] - Laitling was approved by the U.S. FDA in January 2022 and has also been approved in multiple countries, including Australia, Russia, South Korea, the UK, and the EU [3] - As a compound formulation, Laitling offers patients a more convenient and effective treatment option, improving patient compliance [3]

Macro Strategy and North Exchange - The macro policy remains stable with LPR unchanged at 3.10% for 1-year and 3.60% for 5-year [5] - Industrial enterprise profits showed a year-on-year increase of 2.60% in March, marking the first positive growth since the previous year [5] - The Central Political Bureau emphasized the need for high-quality development to address international economic and trade struggles, focusing on "Four Stabilities" [7][8] - The government plans to accelerate the issuance of special bonds and long-term bonds, with a deficit rate set at around 4% and a total deficit scale of 5.66 trillion yuan, an increase of 1.6 trillion yuan from 2024 [8] - Monetary policy will include timely reductions in reserve requirements and interest rates, along with new structural monetary policy tools to support innovation and consumption [10][11] A-Share Market Overview - From April 21 to April 27, 2025, most A-share indices rose, with the Shanghai Composite Index increasing by 0.56% and the Shenzhen Component Index by 1.38% [15] - The market is expected to maintain a narrow fluctuation state due to the recent "reciprocal tariffs" imposed by the US and the upcoming May Day holiday [15][23] - The report indicates a "slow bull" market trend for A-shares in 2025, with a focus on technology, green energy, consumption, and infrastructure sectors [23] North Exchange Market Overview - As of April 25, 2025, the North Exchange had 265 listed stocks, with an average total market value of 755.47 billion yuan, an increase of 1.53% from the previous week [24] - The liquidity in the North Exchange decreased, with average trading volume dropping by 9.79% to 1.384 billion shares [25] - The North Exchange's 50 Index closed at 1300.19 points, down 2.16% from the previous week [26] Industry Insights: Food and Beverage - Salted Fish reported a revenue of 5.304 billion yuan and a net profit of 640 million yuan for 2024, reflecting a year-on-year increase of 28.89% and 26.53% respectively [34] - The company is focusing on core product categories with strong growth, particularly in spicy snacks and baked goods, with significant revenue increases [35] - Salted Fish is accelerating its overseas expansion, with a projected revenue of 6.678 billion yuan in 2025, growing at 25.9% year-on-year [38] Industry Insights: Medical Devices - The sales of ultrasound imaging devices showed a significant recovery in Q1 2025, with sales revenue increasing by 87.95% year-on-year [40] - The report highlights a shift towards domestic brands, with domestic sales accounting for 37.79% of the market share in 2024, up from 34.20% in 2023 [42] - The report suggests a positive outlook for domestic ultrasound device manufacturers like Mindray and KAILI Medical, as the market for these devices is expected to continue recovering [48]